No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NBTX Nanobiotix
- 4.600
- -0.750-14.02%
Close Jun 14 16:00 ET
- 4.540
- -0.060-1.30%
Post 19:52 ET
216.71MMarket Cap-3965P/E (TTM)
5.000High4.600Low20.24KVolume5.000Open5.350Pre Close97.08KTurnover0.09%Turnover RatioLossP/E (Static)47.11MShares11.00052wk High-109.52P/B104.84MFloat Cap4.60052wk Low--Dividend TTM22.79MShs Float21.550Historical High--Div YieldTTM7.48%Amplitude1.750Historical Low4.796Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Nanobiotix Announced New Data At ASCO 2924, Showing 48% ORR In Evaluable Anti-PD-1 Naïve Patients (N=25); 28% ORR In Evaluable Anti-PD-1 Resistant Patients (N=25) As Per RECIST 1.1
NANOBIOTIX (NASDAQ:NBTX) today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoin
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By Anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior Anti-PD-1 Therapy
Analysts Are Bullish on Top Healthcare Stocks: Capitol Health Limited (AU:CAJ), Nanobiotix (GB:0QAV)
Nanobiotix to Unveil NBTXR3 Study Results at ASCO
NANOBIOTIX Announces Presentation of New Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer
Comments
$Nanobiotix(NBTX.US$
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, whe...
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, whe...
1
$Nanobiotix(NBTX.US$
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announced new data from Study 1100, showing disease control and tumor response in patients treated with RT-activated NBTXR3 followed by anti-PD-1 therapy for second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The stud...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announced new data from Study 1100, showing disease control and tumor response in patients treated with RT-activated NBTXR3 followed by anti-PD-1 therapy for second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The stud...
$Nanobiotix(NBTX.US$
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) has announced the presentation of new data from its US Phase 1 Study 1100 at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO). The study evaluates NBTXR3 combined with anti-PD-1 therapy in patients with recurre...
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) has announced the presentation of new data from its US Phase 1 Study 1100 at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO). The study evaluates NBTXR3 combined with anti-PD-1 therapy in patients with recurre...
$Nanobiotix(NBTX.US$
NEWS
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix has announced significant progress in its global collaboration with Janssen to develop and commercialize its radioenhancer NBTXR3. This collaboration aims to expand the application of NBTXR3 in treating cancer patients who undergo radiotherapy. Key updates include the removal of a planned futility analysis for the ongoing Phas...
NEWS
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix has announced significant progress in its global collaboration with Janssen to develop and commercialize its radioenhancer NBTXR3. This collaboration aims to expand the application of NBTXR3 in treating cancer patients who undergo radiotherapy. Key updates include the removal of a planned futility analysis for the ongoing Phas...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg